【Abstract】 Objective To observe the clinical efficacy of Biyuan Tongqiao granule combined with pidotimod in children with allergic rhinitis and provide clinical data for the treatment of allergic rhinitis. Methods 213 children with allergic rhinitis were randomly divided into group A, group B and group C. The group A, group B and group C were treated with nasolabria through Tongqiao granule, Pidotimod, and Xueyuan Tongqiao granule combined with Pidotimod, respectively. Clinical symptom scores before and after treatment, nasal secretion of inflammatory substances, clinical indicators and adverse reactions were observed.Results The clinical symptom scores, nasal secretions inflammatory substances content and clinical indicators of the three groups were significangly different(P＜005). The clinical symptom scores, nasal secretions inflammatory substances content and clinical indicators of group C were lower than that of group A and group C. The nausea/vomiting, bosom frowsty, total number of adverse reactions of the three groups were siginificant different. The nausea/vomiting, bosom frowsty, total number of adverse reactions of group C were lower than that of group A and group C. Conclusion BHD can be clinically effective in treating childhood allergic rhinitis.